ERBB2 and ovarian cancer: We continually evaluated the in vivo antitumor efficacy of Tra-CASTi-MMAE in HER2-positive human ovarian cancer SK-OV-3 (HER2 + ++) and human breast ductal adenocarcinoma JIMT-1 (HER2 + +) xenograft models32,33.